Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).
about
Calcitonin gene-related peptide: physiology and pathophysiologyPossible site of action of CGRP antagonists in migraine.The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system.Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.Migraine associated with gastrointestinal disorders: review of the literature and clinical implications.Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead.Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.The influence of migraine and female hormones on capsaicin-induced dermal blood flow.Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.Calcitonin gene-related peptide and pain: a systematic review.The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine.Calcitonin gene-related peptide receptor antagonists for migraine.Chemical mediators of migraine: preclinical and clinical observations.Antidromic vasodilatation and the migraine mechanism.Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.Optimizing Central Nervous System Drug Development Using Molecular Imaging.Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects.A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan.The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.Influence of varying estrogen levels on trigeminal CGRP release in healthy women.Gender aspects of CGRP in migraine.The relationship between migraine and rosacea: Systematic review and meta-analysis.The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel.A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina.Effect of telcagepant on spontaneous ischemia in cardiovascular patients in a randomized study.Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease
P2860
Q28249298-CC6ED404-48A3-4AF4-B827-DE6F9528F6A1Q34169056-40BAAEE7-CE54-4A2A-A363-A29DFC08C16AQ34228530-B2F55972-EA49-4AD9-B1AF-FCDD7745CEB7Q34446715-8FA5A237-C18D-491F-A241-F011180582A1Q34554827-590D7AB7-AFB1-43F9-B00B-7890DA0C2568Q35082079-C442EDCD-9E0A-4B89-96E6-3C7E32F16DD0Q35675308-985D24A2-6CFF-4AFB-984D-F6EEFAD05C46Q36149333-19B6FE59-53BF-4630-869F-4205DB8F111BQ37593097-DD53DAAA-8A57-4A34-8F8C-7D6573696699Q37707191-A788F25D-FAEA-4BE3-B7F8-F1589D883335Q37713262-E87E236D-28FB-4F5C-8C36-91B01708A39EQ37756158-DD59A5EA-8349-45BF-8EC0-6FE42D28036FQ37883455-ACE486AD-8A7E-4327-A5B4-AA3EAA50E5E0Q37971447-35B26962-D3B5-4AA3-B673-A171E1026449Q38130336-90A6FB89-AF64-4CC6-A9D1-91E7F4DDEE39Q38419418-DFDE140D-9EEA-4546-A610-9CC64237228BQ38665422-7745C2ED-8E85-442C-B500-0D89FAA32054Q38737085-A0BBCB43-1AD4-44FE-B34B-B0D1C0DF7EB6Q40867528-807B4C28-954C-46FB-BA7E-FF1CB3AFF29BQ42732396-1B591B88-F7C8-4FDF-8BA3-226BC99D3FBFQ43885764-9489E7DA-B6EB-4519-AC4B-F02C99A074B9Q46077794-7013D59D-998B-4B38-AE40-933AFCB82048Q46516472-0CA6639B-98A3-4E71-8EA2-BE3BC69A49B0Q47595416-5E6EC239-FFA8-4D38-AA7D-1063D0D4619DQ47944255-20C83490-D85B-4ED5-9637-87767240E95CQ48264984-5BCF64C8-48DF-4B23-8B36-C85D52D4141AQ48745119-3AFE5DB6-1DDC-429E-B7B6-DCC95C9695F7Q48859221-26BAFD68-C062-4184-B9D6-D6512D5BF2BCQ57197707-1CDF461E-F283-4A81-88D2-325CE8DB65AE
P2860
Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@ast
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@en
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@nl
type
label
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@ast
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@en
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@nl
prefLabel
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@ast
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@en
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@nl
P2093
P2860
P50
P1476
Inhibition of capsaicin-induce ...... gonist, telcagepant (MK-0974).
@en
P2093
Anne Van Hecken
Bart J Van der Schueren
Floris H M Vanmolkot
Inge de Lepeleire
Janet Boyle
Jay N de Hoon
John Palcza
Kenneth J Willson
Lisa Hickey
P2860
P356
10.1111/J.1365-2125.2009.03543.X
P407
P577
2010-01-01T00:00:00Z